David Cory
Last updated on 2016-08-16T10:05+0300.

About this image

Extracted quotes from
David Cory said
:
"The FDA approval of Zokinvy is the result of a pioneering partnership between Eiger BioPharmaceuticals and (PRF) to bring the first approved therapy to children, young adults and families living with this devastating disease,"
prnewswire Wednesday, November 25, 2020 5:13:00 PM EAT
David Cory said
:
"The sale of the PRV provides Eiger with an important source of non-dilutive capital and further strengthens our balance sheet. The proceeds allow us to continue to ensure that all diagnosed children and young adults worldwide with Progeria and processing-deficient Progeroid Laminopathies have access to Zokinvy and to advance our late-stage pipeline that now includes three breakthrough therapy designated programs,"
prnewswire Monday, November 23, 2020 4:23:00 PM EAT
David Cory said
:
"A therapy has been long overdue for this community,"
prnewswire Saturday, November 21, 2020 3:35:00 AM EAT
David Cory said
:
"The FDA approval of Zokinvy is the result of a pioneering partnership between Eiger BioPharmaceuticals and PRF to bring the first approved therapy to children, young adults and families living with this devastating disease,"
4-traders Saturday, November 21, 2020 2:58:00 AM EAT
David Cory said
:
"The FDA approval of Zokinvy is the result of a pioneering partnership between Eiger BioPharmaceuticals and PRF to bring the first approved therapy to children, young adults and families living with this devastating disease,"
prnewswire Saturday, November 21, 2020 1:59:00 AM EAT
David Cory said
:
"Lambda is in late stage development for the treatment of Hepatitis Delta Virus (HDV), the most severe form of human viral hepatitis, and HDV is our lead clinical program,"
news-yahoo Monday, September 28, 2020 3:23:00 PM EAT
David Cory said
:
"Eiger is executing toward multiple important milestones across our pipeline, including anticipated FDA approval of Zokinvy in Progeria and Progeroid Laminopathies,"
prnewswire Thursday, August 6, 2020 11:17:00 PM EAT
David Cory said
:
"The acceptance of our first NDA is a significant milestone for Eiger, and an important step toward bringing a treatment to children and young adults with Progeria and Progeroid Laminopathies,"
news-yahoo Tuesday, May 19, 2020 11:40:00 PM EAT
David Cory said
:
"We are committed to the Progeria community, including The Progeria Research Foundation and Progeria Family Circle, to bring the first approved treatment to children and young adults with Progeria and Progeroid Laminopathies,"
4-traders Monday, March 23, 2020 3:41:00 PM EAT
David Cory said
:
"We are pleased to announce the submission of the MAA for lonafarnib in Progeria and Progeroid Laminopathies and look forward to completing the NDA submission by end of the month as planned,"
4-traders Friday, March 13, 2020 3:32:00 PM EAT
David Cory said
:
"We are pleased to announce the submission of the MAA for lonafarnib in Progeria and Progeroid Laminopathies and look forward to completing the NDA submission by end of the month as planned,"
news-yahoo Friday, March 13, 2020 3:30:00 PM EAT
David Cory said
:
"We are excited to welcome Eldon Mayer as our Executive Vice President and Chief Commercial Officer. Eldon is a seasoned leader who brings extensive experience in building and managing high performance commercial teams, as well as product launch planning and lifecycle management,"
4-traders Tuesday, January 7, 2020 4:10:00 PM EAT
David Cory said
:
"We are excited to welcome Eldon Mayer as our Executive Vice President and Chief Commercial Officer. Eldon is a seasoned leader who brings extensive experience in building and managing high performance commercial teams, as well as product launch planning and lifecycle management,"
prnewswire Tuesday, January 7, 2020 4:10:00 PM EAT
David Cory said
:
"Eiger begins 2020 with four late-stage, FDA Breakthrough Therapy Designation Programs, with first-in-class therapies, targeting rare and ultra-rare diseases with high unmet medical needs with no approved treatments,"
news-yahoo Monday, January 6, 2020 4:47:00 PM EAT
David Cory said
:
"Eiger begins 2020 with four late-stage, FDA Breakthrough Therapy Designation Programs, with first-in-class therapies, targeting rare and ultra-rare diseases with high unmet medical needs with no approved treatments,"
4-traders Monday, January 6, 2020 4:18:00 PM EAT
David Cory said
:
"Our discussions with FDA have been constructive and collaborative at each step, and agency agreement to accept our NDA on a rolling basis marks an important milestone to begin the regulatory review process for Lonafarnib in Progeria and Progeroid Laminopathies,"
news-yahoo Tuesday, December 17, 2019 2:27:00 AM EAT
David Cory said
:
"Our discussions with FDA have been constructive and collaborative at each step, and agency agreement to accept our NDA on a rolling basis marks an important milestone to begin the regulatory review process for Lonafarnib in Progeria and Progeroid Laminopathies,"
4-traders Tuesday, December 17, 2019 2:09:00 AM EAT
David Cory said
:
"Our discussions with FDA have been constructive and collaborative at each step, and agency agreement to accept our NDA on a rolling basis marks an important milestone to begin the regulatory review process for Lonafarnib in Progeria and Progeroid Laminopathies,"
prnewswire Tuesday, December 17, 2019 1:53:00 AM EAT
David Cory said
:
"Our avexitide PBH clinical program has dosed 54 patients across four Phase 2 studies, involving both inpatient and outpatient treatment, with promising results for patients suffering from post-bariatric hypoglycemia,"
4-traders Monday, June 17, 2019 11:37:00 PM EAT
David Cory said
:
"Eiger is on track to file the first-ever NDA and MAA for Progeria and Progeroid Laminopathies in 2019,"
4-traders Thursday, May 9, 2019 11:41:00 PM EAT
David Cory said
:
“This guy bought these properties years and years ago,”
wkbw Friday, March 29, 2019 3:31:00 AM EAT
David Cory said
:
"We are delivering on our founding commitment to rapidly advance only the most promising rare disease programs, adding strategic and complementary programs to the pipeline in the process,"
4-traders Tuesday, December 11, 2018 10:45:00 PM EAT
David Cory said
:
"Eiger has continued to make significant progress in 2016 in advancing our pipeline of novel products for the treatment of orphan diseases and positioning the company for multiple near-term potentially value-creating events,"
prnewswire Tuesday, November 8, 2016 5:07:00 PM EAT
David Cory said
:
"Quantum devices have the potential to change the world. We would like to see this happen,"
CBC Tuesday, September 6, 2016 8:51:00 PM EAT
Key Titles and Phrases | Count | Lang | Last Seen |
---|---|---|---|
president | 57.14% | EN | 01/30/201730/01/2017 |
deputy director of iqc | 42.86% | EN | 10/18/201618/10/2016 |
Names | Lang | Count |
---|---|---|
David Cory | EN | 88.89% |
David Cory | FR | 11.11% |
Type | Entity Name | Count |
---|---|---|
![]() | Risk Factors | 7.64% |
![]() | Drug Administration | 7.64% |
![]() | Inc | 6.94% |
![]() | European Union | 5.21% |
![]() | Research Foundation | 3.82% |
![]() | Francis Collins | 3.47% |
![]() | Kader Yilmaz | 3.47% |
![]() | Access Program | 3.12% |
![]() | Merck Sharp | 2.08% |
![]() | Medicines Agency | 2.08% |
![]() | European Medicines Agency | 2.08% |
![]() | Thomas Dietz | 1.74% |
![]() | Leslie Gordon | 1.74% |
![]() | Association | 1.39% |
![]() | Supply Agreement | 1.39% |
![]() | United Nations | 1.04% |
![]() | Clinical Development | 1.04% |
![]() | Schering Plough | 1.04% |
![]() | Alain Beaudet | 0.69% |
![]() | Michael Houghton | 0.69% |
![]() | Ted | 0.69% |
![]() | McGill University | 0.69% |
![]() | Guy Breton | 0.69% |
![]() | Kirsty Duncan | 0.69% |
![]() | Mario Pinto | 0.69% |
![]() | Research Council | 0.69% |
![]() | Paul Corkum | 0.69% |
![]() | Jürgen Mlynek | 0.69% |
![]() | Andrew White | 0.69% |
![]() | Peter Zoller | 0.69% |
Type | Entity Name | Score |
---|---|---|
![]() | Kader Yilmaz | 0.0746 |
![]() | Paul Corkum | 0.0588 |
![]() | Jürgen Mlynek | 0.0571 |
![]() | Thomas Dietz | 0.0347 |
![]() | Peter Zoller | 0.0253 |
![]() | Risk Factors | 0.0207 |
![]() | Alain Beaudet | 0.0157 |
![]() | William Richardson | 0.0128 |
![]() | Drug Administration | 0.0106 |
![]() | Research Foundation | 0.0102 |
![]() | Francis Collins | 0.0097 |
![]() | Access Program | 0.0088 |
![]() | Neil Gershenfeld | 0.0077 |
![]() | Guy Breton | 0.0064 |
![]() | Leslie Gordon | 0.0063 |
![]() | Merck Sharp | 0.0059 |
![]() | Medicines Agency | 0.0053 |
![]() | European Medicines Agency | 0.005 |
![]() | Inc | 0.0044 |
![]() | Stephen Patrick | 0.0043 |
![]() | Supply Agreement | 0.0039 |
![]() | Elizabeth Cannon | 0.0032 |
![]() | Clinical Development | 0.003 |
![]() | Schering Plough | 0.003 |
![]() | Brian Needham | 0.003 |
![]() | Steve Johns | 0.0027 |
![]() | Mario Pinto | 0.0024 |
![]() | Sean Newman | 0.0024 |
![]() | Christopher Johnstone | 0.0022 |
![]() | Joanna Reid | 0.0021 |


Tools
Select your languages
Interface:
Explore Relations
The selection and placement of stories are determined automatically by a computer program.
This site is supplied by the Situation Room of the Continental Early Warning System (CEWS) of the Peace and Security Department of the African Union Commission. The project is supported by the Joint Research Centre of the EU Commission
Please send any comments or suggestions to
The information on this site is subject to adisclaimer.